|
|
SGLT2抑制剂在肾脏保护方面的研究进展
|
Abstract:
钠–葡萄糖协同转运蛋白2 (sodium-glucose cotransporter-2, SGLT2)抑制剂是一种新型降糖药物，在降糖的同时可改善2型糖尿病患者心血管及肾脏结局。近期研究发现，其在治疗非糖尿病导致的慢性肾脏病(chronic kidney disease, CKD)同样具有肾脏保护作用，这为CKD的治疗提供了新方向和新思路。现对于SGLT2抑制剂治疗CKD的作用机制以及安全性仍在探索中，本文就SGLT2抑制剂在肾脏获益方面的研究进展及其可能的机制进行简要综述，旨在为CKD患者的治疗提供临床参考。
Sodium-glucose cotransporter-2 (sodium-glucose cotransporter-2, SGLT2) inhibitor is a novel hypo-glycemic drug that can improve cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. Recent studies have found that it also has renal protective effect in the treatment of chronic kidney disease (CKD) not caused by diabetes, which provides a new direction and new ideas for the treatment of CKD. Currently, the mechanism and safety of SGLT2 inhibitors in the treatment of CKD are still being explored. In this review, the research progress of SGLT2 inhibitors in kidney benefit and their possible mechanisms are briefly reviewed, aiming to provide clinical reference for the treatment of patients with CKD.
| [1] | Wheeler, D.C., Stefánsson, B.V., Jongs, N., Chertow, G.M., Greene, T., Hou, F.F., et al. (2021) Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients with Diabetic and Non-Diabetic Chronic Kidney Dis-ease: A Prespecified Analysis from the DAPA-CKD Trial. The Lancet Diabetes & Endocrinology, 9, 22-31.
https://doi.org/10.1016/S2213-8587(20)30369-7 |
| [2] | Heerspink, H.J., Desai, M., Jardine, M., Balis, D., Meining-er, G. and Perkovic, V. (2017) Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. Journal of the American Society of Nephrology, 28, 368-375. https://doi.org/10.1681/ASN.2016030278 |
| [3] | 李航. 肾脏在血糖调节中的作用[J]. 中国糖尿病杂志, 2016, 24(2): 184-186. |
| [4] | Ni, L., Yuan, C., Chen, G., Zhang, C. and Wu, X. (2020) SGLT2i: Beyond the Glucose-Lowering Effect. Cardiovascular Diabetology, 19, Article No. 98. https://doi.org/10.1186/s12933-020-01071-y |
| [5] | Kawanami, D., Matoba, K., Takeda, Y., Nagai, Y., Akamine, T., Yokota, T., et al. (2017) SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy. International Journal of Molecular Sciences, 18, Article No. 1083.
https://doi.org/10.3390/ijms18051083 |
| [6] | Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377, 644-657.
https://doi.org/10.1056/NEJMoa1611925 |
| [7] | Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Na-katsuka, A., et al. (2014) Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ame-liorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice. PLoS ONE, 9, Article ID: e100777. https://doi.org/10.1371/journal.pone.0100777 |
| [8] | Sanidas, E.A., Papadopoulos, D.P., Hatziagelaki, E., Grassos, C., Velliou, M. and Barbetseas, J. (2020) Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors across the Spectrum of Hypertension. American Journal of Hypertension, 33, 207-213. https://doi.org/10.1093/ajh/hpz157 |
| [9] | Scheen, A.J. (2019) Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Current Cardiology Reports, 21, Article No. 70. https://doi.org/10.1007/s11886-019-1165-1 |
| [10] | Vallon, V. and Thomson, S.C. (2017) Targeting Renal Glucose Reabsorption to Treat Hyperglycaemia: The Pleiotropic Effects of SGLT2 Inhibition. Diabeto-logia, 60, 215-225. https://doi.org/10.1007/s00125-016-4157-3 |
| [11] | Casta？eda, A.M., Dutra-Rufato, A., Juarez, M.J., Grosembacher, L., Gonzalez-Torres, H. and Musso, C.G. (2021) Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): Renal Implications. International Urology and Nephrology, 53, 291-299. https://doi.org/10.1007/s11255-020-02585-w |
| [12] | Zhang, L., Zhao, M.H., Zuo, L., Wang, Y., Yu, F., Zhang, H., et al. (2020) China Kidney Disease Network (CK-NET) 2016 Annual Data Report. Kidney International Supplements, 10, e97-e185. https://doi.org/10.1016/j.kisu.2020.09.001 |
| [13] | Wheeler, D.C., Stefansson, B.V., Batiushin, M., Bilchenko, O., Cherney, D.Z.I., Chertow, G.M., et al. (2020) The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) Trial: Baseline Characteristics. Nephrology, Dialysis, Transplantation, 35, 1700-1711. https://doi.org/10.1093/ndt/gfaa234 |
| [14] | Becker, M.A., Schumacher, H.R., Espinoza, L.R., Wells, A.F., MacDonald, P., Lloyd, E., et al. (2010) The Urate- Lowering Efficacy and Safety of Febuxostat in the Treatment of the Hyperuricemia of Gout: The CONFIRMS Trial. Arthritis Research & Therapy, 12, Article No. R63. https://doi.org/10.1186/ar2978 |
| [15] | Mcgill, J.B. (2014) The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: A Bench to Bedside Review. Diabetes Therapy, 5, 43-63. https://doi.org/10.1007/s13300-014-0063-1 |
| [16] | Ahmadieh, H. and Azar, S. (2017) Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus. Diabetes Technology & Therapeutics, 19, 507-512. https://doi.org/10.1089/dia.2017.0070 |
| [17] | Andres-Hernando, A., Lanaspa, M.A., Kuwabara, M., Or-licky, D.J., Cicerchi, C., Bales, E., et al. (2019) Obesity Causes Renal Mitochondrial Dysfunction and Energy Imbalance and Accelerates Chronic Kidney Disease in Mice. American Journal of Physiology Renal Physiology, 317, F941-F948. https://doi.org/10.1152/ajprenal.00203.2019 |
| [18] | Tsimihodimos, V., Filippatos, T.D. and Elisaf, M.S. (2018) SGLT2 Inhibitors and the Kidney: Effects and Mechanisms. Diabetes & Metabolic Syndrome, 12, 1117-1123. https://doi.org/10.1016/j.dsx.2018.06.003 |
| [19] | Consoli, A., Formoso, G., Baldassarre, M.P.A. and Febo, F. (2018) A Comparative Safety Review between GLP-1 Receptor Agonists and SGLT2 Inhibitors for Diabetes Treatment. Expert Opinion on Drug Safety, 17, 293-302.
https://doi.org/10.1080/14740338.2018.1428305 |
| [20] | Babitt, J.L. and Lin, H.Y. (2012) Mechanisms of Anemia in CKD. Journal of the American Society of Nephrology, 23, 1631-1634. https://doi.org/10.1681/ASN.2011111078 |
| [21] | Tsai, S.F. and Tarng, D.C. (2019) Anemia in Patients of Diabetic Kidney Disease. Journal of the Chinese Medical Association, 82, 752-755. https://doi.org/10.1097/JCMA.0000000000000175 |
| [22] | Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheri-adou, I. and Tentolouris, N. (2019) SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. In-ternational Journal of Environmental Research and Public Health, 16, Article No. 2965. https://doi.org/10.3390/ijerph16162965 |
